Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a cheaper copy of ocrevus work just as well for MS?

NCT ID NCT06847724

Disease control Sponsor: Sandoz Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether CYB704, a proposed biosimilar to the MS drug Ocrevus, works the same way in the body. About 183 people with relapsing multiple sclerosis will receive either CYB704 or Ocrevus. Researchers will compare drug levels, MRI scans, and side effects to see if the biosimilar is a viable alternative.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ocrelizumab (proposed biosimilar CYB704)
What this could lead to
If successful, CYB704 could offer a more affordable treatment option for relapsing multiple sclerosis, potentially increasing access to care.
What could go wrong
This is a biosimilar study, not a new drug. Even if CYB704 matches Ocrevus in the body, long-term safety and effectiveness still need confirmation. As with Ocrevus, risks include infusion reactions and increased infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

183 people

The number who actually took part.

Started

Jun 2025

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of RMS (relapsing remitting multiple sclerosis (MS) or active secondary progressive MS) * Evidence of recent disease activity as defined in study protocol * Expanded Disability Status scale score of 0 to 5.5 (inclusive) at screening * Neurological stability (no new signs or symptoms referable to Central Nervous System (CNS) within 30 days before both screening and first study treatment Exclusion Criteria: * Diagnosis of primary progressive MS * Disease duration of more than 10 years in participants with an Expanded Disability Status Scale (EDSS) ≤2.0 at screening * Inability to complete an MRI or contraindication to gadolinium administration * History of allergic or anaphylactic reactions to ocrelizumab or one of the premedications (methylprednisolone or equivalent corticosteroid, antihistamine, antipyretic) * Pregnant participants * Current or history of medical conditions as outlined in the study protocol * Prohibited medications (current and history) as outlined in the study protocol * Abnormal laboratory blood values as outlined in the study protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Relapsing multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Relapsing multiple sclerosis

Contacts and locations

Locations

  • Sandoz Investigational Site

    Maitland, Florida, 32751, United States

  • Sandoz Investigational Site

    Ormond Beach, Florida, 32174, United States

  • Sandoz Investigational Site

    Banja Luka, Bosnia and Herzegovina

  • Sandoz Investigational Site

    Bihać, Bosnia and Herzegovina

  • Sandoz Investigational Site

    Sarajevo, Bosnia and Herzegovina

  • Sandoz Investigational Site

    Pleven, Bulgaria

  • Sandoz Investigational Site

    Plovdiv, Bulgaria

  • Sandoz Investigational Site

    Sofia, Bulgaria

  • Sandoz Investigational Site

    Varaždin, Croatia

  • Sandoz Investigational Site

    Zagreb, Croatia

  • Sandoz Investigational Site

    Rustavi, Georgia

  • Sandoz Investigational Site

    Tbilisi, Georgia

  • Sandoz Investigational Site

    Shtip, North Macedonia

  • Sandoz Investigational Site

    Skopje, North Macedonia

  • Sandoz Investigational Site

    Bydgoszcz, Poland

  • Sandoz Investigational Site

    Katowice, Poland

  • Sandoz Investigational Site

    Lodz, Poland

  • Sandoz Investigational Site

    Lublin, Poland

  • Sandoz Investigational Site

    Nowa Sól, Poland

  • Sandoz Investigational Site

    Poznan, Poland

  • Sandoz Investigational Site

    Szczecin, Poland

  • Sandoz Investigational Site

    Warsaw, Poland

  • Sandoz Investigational Site

    Zabrze, Poland

  • Sandoz Investigational Site

    Belgrade, Serbia

  • Sandoz Investigational Site

    Niš, Serbia

  • Sandoz Investigational Site 2

    Sarajevo, Bosnia and Herzegovina

  • Sandoz Investigational Site 2

    Plovdiv, Bulgaria

  • Sandoz Investigational Site 2

    Sofia, Bulgaria

  • Sandoz Investigational Site 2

    Tbilisi, Georgia

  • Sandoz Investigational Site 2

    Katowice, Poland

  • Sandoz Investigational Site 2

    Lublin, Poland

  • Sandoz Investigational Site 2

    Poznan, Poland

  • Sandoz Investigational Site 3

    Sofia, Bulgaria

  • Sandoz Investigational Site 3

    Tbilisi, Georgia

  • Sandoz Investigational Site 4

    Sofia, Bulgaria

  • Sandoz Investigational Site 4

    Tbilisi, Georgia

  • Sandoz Investigational Site 5

    Sofia, Bulgaria

  • Sandoz Investigational Site 5

    Tbilisi, Georgia

  • Sandoz Investigational Site 6

    Tbilisi, Georgia

  • Sandoz Investigational Site 7

    Tbilisi, Georgia

  • Sandoz Investigational Site 8

    Tbilisi, Georgia

More trials for these conditions

Other studies related to the condition(s) this trial covers.